Fig. 5: Persistence and re-expansion of CRISPR-edited anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO in patients. | Cell Discovery

Fig. 5: Persistence and re-expansion of CRISPR-edited anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO in patients.

From: CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy

Fig. 5

a–c Left panel, kinetics of CAR vector copies in the blood of treated patients and frequencies of CRISPR-edited CD3– CART cells. Right panel, analysis of CD3+ and CD3– CAR+ T cells in patient samples during long-term follow-up. c BCMA expression on lymphocytes of peripheral blood in patient #3 at D177 post infusion.

Back to article page